Credible journalism, Incredible reach

Market One Media Group is a collaborative content marketing, strategy and creation agency with a stable of award winning journalists and videographers focused on providing robust solutions for Canada’s capital markets. Our multi-channel approach is to inform, inspire and ignite conversations with exclusive content published across North America’s most credible print, digital, and broadcast television platforms.

Custom Content Creation

A tool used by companies to educate, inform or entertain consumers or investors by producing pieces that create attention or cause behavior to result in leads, sales or advocacy.

Targeted Distribution

The strategic placement of content pieces to maximize effectiveness, and includes the use of trusted and credible third-party platforms and direct-to-user engagement tactics

Custom Content Creation

Targeted Distribution

BROADCAST REACH

1,300,000+

WEEKLY READERS

7,900,000+

UNIQUE VISITORS

10,000,000

Have your company featured on

What our Clients say

Market Trends

Novel drug offers hope for brain cancer patients

MDNA55 covering the rGBM tumor and surrounding margins where relapse is likely to occur.

By Jason Smith
 

• Glioblastoma multiforme (“GBM”) is uniformly fatal

• A new drug in clinical trials offers hope to patients who have failed other treatments

• Medicenna’s MDNA55 targets tumors and unblinds the immune system by purging the protective tumor micro-envir

More

Canada’s leading Fintech and financing conference

FFCON 2019 emphasizes fearlessness in Fintech

By Ryan Aceman
 

• #FFCON19 is set to showcase the importance of being fearless to succeed in Fintech

• 12 cutting-edge companies will compete in a ground-breaking pitch competition

• Key emerging trends from tech and investment realms will be highlighted

 
Where finance and technology meet, lies one of the most fascinating sector

More

A unique medical approach to treat cancer (Video)

Oncolytics is developing an intravenously delivered immuno-oncolytic virus called Pelareorep.

Oncolytics Biotech Inc. (TSX: ONC) is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) i

More